Literature DB >> 18827427

Chronic myeloid leukemia following chemotherapy with 5'-deoxy-5-fluorouridine for gastric cancer.

Motohiro Tsuzuki1, Kousuke Handa, Kiyoko Yamamoto, Akio Hasegawa, Yukiya Yamamoto, Masato Watanabe, Syuichi Mizuta, Fumio Maruyama, Masataka Okamoto, Nobuhiko Emi, Kohji Ezaki.   

Abstract

We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5'-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5'-DFUR treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827427     DOI: 10.2169/internalmedicine.47.1072

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Chronic myelogenous leukemia after postoperative adjuvant S-1 therapy for rectal cancer: a case report.

Authors:  Masahiro Manabe; Takafumi Nishii; Junya Okita; Johji Nagasaki; Naonori Harada; Yasutaka Aoyama; Takeo Kumura; Tadanobu Ohta; Yoshio Furukawa; Kazuhiro Takeuchi; Atsuko Mugitani
Journal:  Am J Blood Res       Date:  2013-12-18

2.  Medical conditions and risk of adult myeloid leukemia.

Authors:  Kimberly J Johnson; Cindy M Blair; James M Fink; James R Cerhan; Michelle A Roesler; Betsy A Hirsch; Phuong L Nguyen; Julie A Ross
Journal:  Cancer Causes Control       Date:  2012-05-11       Impact factor: 2.506

3.  Liver cancer concurrent with chronic myelocytic leukemia and extreme thrombocytosis: a rare case report.

Authors:  Ping Han; Zhi-Qiang Han; Xia Mao; Jin Wang; Qin-Lu Li; Min Xiao; Li Meng; De-An Tian; Zhen-Ya Hong
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.